Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsBuildingsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zhengye Biotechnology Holding (ZYBT) Receivables (2023 - 2025)

Zhengye Biotechnology Holding has reported Receivables over the past 3 years, most recently at $2.7 million for Q4 2025.

  • Quarterly Receivables fell 74.77% to $2.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $2.7 million through Dec 2025, down 74.77% year-over-year, with the annual reading at $2.7 million for FY2025, 75.31% down from the prior year.
  • Receivables was $2.7 million for Q4 2025 at Zhengye Biotechnology Holding, down from $5.2 million in the prior quarter.
  • Over five years, Receivables peaked at $10.7 million in Q4 2024 and troughed at $2.7 million in Q4 2025.
  • The 3-year median for Receivables is $7.8 million (2023), against an average of $7.3 million.
  • Year-over-year, Receivables grew 2.5% in 2024 and then crashed 74.77% in 2025.
  • A 3-year view of Receivables shows it stood at $10.5 million in 2023, then rose by 2.5% to $10.7 million in 2024, then crashed by 74.77% to $2.7 million in 2025.
  • Per Business Quant, the three most recent readings for ZYBT's Receivables are $2.7 million (Q4 2025), $5.2 million (Q2 2025), and $10.7 million (Q4 2024).